| Project/Area Number |
22790517
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | The Institute of Physical and Chemical Research |
|---|
Principal Investigator |
SHUKURI Miho 独立行政法人理化学研究所, 分子プローブ機能評価研究チーム, 研究員 (20525571)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | シクロオキシゲナーゼ / 非ステロイド性抗炎症薬 / PET / 脳炎症 / ミクログリア / 神経変性疾患 / LPS / アラキドン酸カスケード / 脳内炎症 |
|---|
| Research Abstract |
In order to develop the imaging agent for the in vivo monitoring of COXs activity and/or expression, a series of 2-arylpropionic acid derivatives of NSAIDs were labeled with 11C. Among them, we found that^<11> C-labeled ketoprofen-methyl ester(KTP-Me), its acid form rather specific to COX-1, showed superior sensitivity to inflammation of rat brain. In addition, our results suggest that^<11> C-KTP-Me recognize the changes of COX-1 expression in brain, and provide new evidence for the specific imaging of microglial activation. PET study in monkeys also showed the high accumulation of^<11> C-KTP-Me in neuroinflammatory area. The safety, biodistribution and kinetics of^<11> C-KTP-Me in both rats and monkeys indicate that it should be acceptable for the use of study in human.
|
